Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for cognitive dysfunction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jul 2022: Trial started, NCT05469009
  2. 21 Jul 2022: Trial registered, NCT05469009

The trials

NCT05469009: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy

State
Under way
Phase
Early Phase 1
People
15 planned
Started
14 Jul 2022
Primary completion
Jul 2029
Arms
Infusion plus Exablate BBBO Treatment
Results
None posted
  1. 14 Jul 2022: Trial started
  2. 21 Jul 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.